Rule 50 of the Patents Rules, 2003
Omitted provision
Rule 50 was part of the deleted Exclusive Marketing Rights chapter of the Patents Rules and has no application to any patent matter today.
Official legal text
Indian drafting practice deletes a provision by omitting it, not by closing the gap. Renumbering would break thousands of existing citations, so the number is retained with a note. Records made while the provision was in force still cite it, which is the main reason this page exists.
Treat this page as a guide. The provision as officially published, along with the Gazette notifications that apply to it, remains the governing text and overrides any simplification here.
What this rule requires, step by step
To understand why Rule 50 exists only as a number, look at the ten years between 1995 and 2005. When India joined the World Trade Organization it accepted the TRIPS Agreement, which requires member countries to grant patents for products in every field of technology. India was allowed extra time for medicines and agricultural chemicals. In exchange for that extra time it had to do two things: accept and store patent applications for such products so they kept their filing date, and give a limited marketing right to certain applicants in the meantime. The stored applications were popularly called mailbox applications. The limited marketing right was the Exclusive Marketing Right, and Chapter V of the Patents Rules, 2003, which included Rule 50, carried its procedure.
The transition period ended on 1 January 2005. From that date India began granting full product patents in these fields, and the Patents (Amendment) Act, 2005 removed Chapter IVA from the Patents Act, 1970. Because the parent sections were gone, the rules that served them had nothing left to operate on, and Rule 50 was omitted. Today a company that wants exclusivity over a new medicine in India must obtain a patent in the ordinary way. There is no shorter route and no separate marketing right to claim, so this rule matters only to readers of legal history.
Why this rule matters
Anyone reading pre-2005 pharmaceutical patent files, academic writing or older office correspondence.
Never in a live matter; only while tracing how India implemented its World Trade Organization commitments.
Nothing enforceable. The rule was withdrawn along with the sections it served.
There is no penalty, but relying on it in advice would rest that advice on law that was withdrawn two decades ago.
How it works in practice
A due diligence file raises an old question
Sarayu Pharma Pvt Ltd of Ahmedabad is being acquired, and the buyer's team reviews every intellectual property document in the company's records. They find a 2003 internal memo describing a plan to obtain an exclusive marketing right for a cardiac drug, with a checklist referring to Chapter V of the Patents Rules. The buyer's analyst flags it as an unresolved right that might still be pending. The company's patent adviser explains the position. The Exclusive Marketing Rights scheme was a temporary measure that ended when product patents became available in India from January 2005, and the rules supporting it, including Rule 50, were omitted. The memo describes a plan that could not be pursued after that date. What matters for the acquisition is whether Sarayu Pharma filed a patent application for the same molecule, whether it was published and examined, and what the claims now cover. The team redirects its search to the patent register, and the historical memo is recorded as background only.
Simplified illustration only. Actual legal outcomes depend on the facts.
Key points to remember
- Rule 50 supported the Exclusive Marketing Rights scheme created by the Patents (Amendment) Act, 1999.
- That scheme was a transitional bridge until India allowed product patents from 1 January 2005.
- The Patents (Amendment) Act, 2005 removed the parent chapter and this rule was omitted with it.
- Exclusivity over a product in India now comes only from a granted patent.
Connected provisions
Every rule traces back to a section. The linked sections are shown apart from the rule because the two are separate instruments, and because a rule that goes beyond its parent section can be challenged. Knowing the parent provision is part of reading the rule properly.
Forms, deadlines and fees
We do not publish fee amounts. The First Schedule sets them, and they differ by category of applicant, such as a natural person, a startup, a small entity or another applicant, and by the mode of filing. Check the Schedule currently in force before you calculate anything. How Indian patent fees work.
Related judgments
Court decisions shape how this provision is applied, but a summary is useful only if it is right. Every case note on this site is read by a legal reviewer before it goes live, and none has been completed for this provision so far. This section will fill in as those reviews finish. How case notes are prepared.
Questions people ask about Rule 50
What were mailbox applications and are they still relevant?
Between 1995 and 2004 India could not grant product patents for medicines, food and agricultural chemicals, but it had to preserve the filing dates of such applications. Those applications were held and are commonly called mailbox applications. From 2005 they were taken up and examined in the normal way. The concept still matters for a small number of old patents whose priority dates fall in that window, but no new mailbox filing is possible. All applications today follow the ordinary route.
Does an omitted rule affect rights granted while it was in force?
Removing a rule does not automatically erase things lawfully done under it, but Exclusive Marketing Rights were time limited by their own terms and the last of them ended long ago. No live exclusive marketing right exists in India. If an old document refers to one, treat it as a historical fact about that period, and check the patent register to see what patent rights, if any, the same party actually holds today.
Reviewing an old Indian patent file?
MYCrave Consultancy helps businesses separate historical paperwork from the patent rights that are actually live today.
You will be speaking with MYCrave Consultancy & Services, the firm that operates this platform. General questions are answered free; matter‑specific work is quoted before anything is done.